Adalimumab (ADA)

BIOLOGICAL3 trials

Sponsors

UCB Pharma SA, AbbVie, JHSPH Center for Clinical Trials

Conditions

Psoriatic ArthritisRheumatoid ArthritisUveitis

Phase 3

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

CompletedNCT03828019

JHSPH Center for Clinical TrialsUveitis

Start: 2019-09-16End: 2024-09-09Updated: 2025-05-16

Phase 4

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

CompletedNCT01500278

UCB Pharma SARheumatoid Arthritis

Start: 2011-12-31End: 2016-01-31Updated: 2018-07-31

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

CompletedNCT02814175

AbbViePsoriatic Arthritis

Start: 2016-08-05End: 2020-03-19Updated: 2020-11-23

Related Papers

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis

Lara D. Veeken2024-09-0212 citations

P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial.

Lara D. Veeken2024-04-011 citations

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials

International Journal of Rheumatic Diseases2023-05-1713 citations

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study.

2022-02-2512 citations

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

2016-11-15122 citations